HLA-A and uveal melanoma: Tebentafusp is a novel, bispecific fusion between a gp100 peptide-HLA-A*02:01 specific TCRαβ domain and a CD3 ScFv currently in use for the treatment of uveal melanoma and malignant melanoma [81,82].